Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
Xeris Biopharma Holdings, Inc. (NASDAQ: XERS)
XERS Stock Predictions and Ratings
WSX Rating:
STRONG BUY
WSX Forecast (1yr):
152.10%
Analyst Rating:
BUY
Analyst Forecast (1yr):
72.60%
XERS Stock Analysis
XERS
PE Ratio:
84.1
XERS
PEG Ratio:
0.4
XERS
Forward EPS Growth (12 month):
197.60%
XERS
PS Ratio:
3.2
XERS
PSG Ratio:
0.1
XERS
Forward Revenue Growth (12 month):
22.20%
XERS Articles
No data was found